問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Division of Thoracic Medicine

Division of Hematology & Oncology

National Taiwan University Hospital Hsin-Chu Branch (在職)

Division of General Internal Medicine

National Taiwan University Cancer Center

Division of General Internal Medicine

Chi Mei Hospital, Liouying

Digestive System Department

Division of Thoracic Medicine

Division of General Internal Medicine

Division of Hematology & Oncology

Tri-Service General Hospital

Division of Infectious Disease

更新時間：2023-09-19

陳冠宇
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

185Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳冠宇

List

338Cases

2022-02-01 - 2028-02-15

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2022-05-01 - 2023-02-23

Others

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2020-12-14 - 2025-07-28

Phase III

Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non- Small Cell Lung Cancer without Actionable Genomic Alterations (TROPION-Lung01)

  • Condition/Disease

    Non- Small Cell Lung Cancer

  • Test Drug

    DS-1062a

Participate Sites
8Sites

Recruiting8Sites

2020-11-01 - 2024-07-22

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-09-15 - 2025-10-08

Phase II

HERTHENA-Lung01: A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects With Previously Treated Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)

  • Condition/Disease

    Non-Small Cell Lung Cancer (NSCLC)

  • Test Drug

    Patritumab Deruxtecan (U3-1402)

Participate Sites
8Sites

Recruiting8Sites

2020-05-18 - 2023-12-31

Others

A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-2 (001)

  • Condition/Disease

    Advanced Solid Tumors、non–small-cell lung cancer、squamous cell carcinoma of the head and neck、squamous tumor agnostic、hepatocellular carcinoma and small-cell lung cancer

  • Test Drug

    ALKS 4230

Participate Sites
6Sites

Recruiting6Sites

2016-03-07 - 2018-12-31

Phase II

A phase Ib/II, open-label, multicenter trial with oral cMET inhibitor INC280 alone and in combination with erlotinib versus platinum with pemetrexed in adult patients with EGFR mutated, cMET-amplified, locally advanced/metastatic non-small cell lung cancer (NSCLC) with acquired resistance to prior EGFR tyrosine kinase inhibitor (EGFR TKI)

  • Condition/Disease

    advanced/metastatic non-small cell lung cancer (NSCLC)

  • Test Drug

    INC280 (capmatinib)

Participate Sites
2Sites

Terminated2Sites

2015-03-13 - 2019-10-24

Phase I/II

A Phase Ib/II study of the ALK inhibitor ceritinib in combination with the CDK4/6 inhibitor LEE011 in patients with ALK-positive non-small cell lung cancer.

  • Condition/Disease

    Non-Small Cell Lung Cancer (NSCLC)

  • Test Drug

    LEE011, LDK378 (ceritinib)

Participate Sites
3Sites

Terminated3Sites

2013-07-09 - 2024-01-07

Phase III

A phase III multicenter, randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive), stage IIIB or IV, non-squamous non-small cell lung cancer

  • Condition/Disease

    Non small cell lung cancer

  • Test Drug

    LDK378

Participate Sites
7Sites

Terminated7Sites

2013-04-01 - 2018-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

1 29 30 31 32 33 34
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB